Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220252574IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USING
US 11.08.2022
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Appl.No 17629309 Applicant University of Louisville Research Foundation, Inc. Inventor Kevin Joseph Sokoloski

Immunomodulatory compositions that include at least one alphavirus capsid protein and methods of using such immunomodulatory compositions. In one aspect, methods of immunomodulating IL-1/TLR signaling in a cell are provided. Such methods typically include contacting the cell with an alphavirus capsid protein or a portion thereof, thereby immunomodulating IL-1/TLR signaling in the cell.

2.20220249611ENGINEERED FIBROBLAST GROWTH FACTOR VARIANTS AS RECEPTOR ANTAGONISTS
US 11.08.2022
Int.Class A61K 38/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
18Growth factors; Growth regulators
Appl.No 17283794 Applicant The Board of Trustees of the Leland Stanford Junior University Inventor Sung Jin Park

The present invention provides methods of screening for proteolytically stable growth factor variants, including, for example variants of human fibroblast growth factor 1 (FGF1). The present invention also provides for FGF1 variants comprising at least one amino acid substitution, an amino acid deletion, an amino acid addition and combinations thereof, wherein the resulting FGF1 variant exhibits increased proteolytic stability as compared to wild-type FGF1, as well as related uses.

3.20220251644TUBE LENS DESIGN FOR IMPROVED DEPTH-OF-FIELD
US 11.08.2022
Int.Class C12Q 1/6869
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6869Methods for sequencing
Appl.No 17723280 Applicant Element Biosciences, Inc. Inventor Steve Xiangling CHEN

Imaging systems and methods comprising imaging a first interior surface and a second interior surface of a flow cell are described. In some embodiments, the imaging systems may comprise: a) an objective lens; b) at least one image sensor; and c) at least one tube lens disposed in an optical path between the objective lens and the at least one image sensor; wherein the at least one tube lens is configured to correct imaging performance such that images of the first interior surface of the flow cell and the second interior surface of the flow cell have substantially the same optical resolution.

4.WO/2022/166103TRANSAMINASE MUTANT AND APPLICATION THEREOF
WO 11.08.2022
Int.Class C12N 9/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
10Transferases (2.)
Appl.No PCT/CN2021/104841 Applicant ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. Inventor HONG, Hao
Provided are a transaminase mutant and an application thereof. The transaminase mutant is obtained by mutating one or more amino acids in SEQ ID NO: 2 or is a mutant obtained by taking the sequence SEQ ID NO: 1 of wild-type CVTA transaminase as a reference and mutating conserved amino acids therein. Compared with wild-type transaminases, the catalytic activity of the mutant is improved to different degrees, so that the production efficiency of chiral amine compound synthesis can be improved.
5.WO/2022/166838CONSTRUCTION AND APPLICATIONS OF ENATIOSELECTIVE FLIPPED ω-TRANSAMINASE MUTANT
WO 11.08.2022
Int.Class C12N 9/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
10Transferases (2.)
Appl.No PCT/CN2022/074737 Applicant ZHEJIANG APELOA KANGYU PHARMACEUTICAL CO., LTD. Inventor LIN, Shuangjun
Provided is a transaminase mutant, having a sequence on which an amino acid mutation takes place on the basis of the sequence as represented by SEQ ID NO: 13. Provided is an enatioselective flipped ω-transaminase ATA-117 mutant. The amino acid sequence of the mutant is as represented by SEQ ID NO: 1; the nucleic acid sequence coding the mutant is as represented by SEQ ID NO: 2. Also provided is a plasmid carrying the nucleic acid sequence, genetically engineered bacteria expressing the ω-transaminase ATA-117 mutant, and a method for producing (1R,2R)-1,3-dihydroxy-2-amino-1-p-methylsulfonylphenylpropane with the ω-transaminase ATA-117 mutant.
6.WO/2022/165608ANTI-SYNUCLEINOPATHY PEPTIDE AND METHODS TO TREAT NEURODEGENRATIVE DISEASES
WO 11.08.2022
Int.Class A61K 47/66
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
66the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
Appl.No PCT/CA2022/050175 Applicant UNIVERSITY OF BRITISH COLUMBIA Inventor WANG, Yu Tian
Disclosed is a method of treating a neurodegenerative disease such as Parkinson's disease, diffuse Lewy body disease, transitional Lewy body dementia, and multiple system atrophy in a subject. The method comprises administering to the subject a therapeutically effective amount of a peptide comprising an α-synuclein binding domain operably linked to a protein transduction domain and a proteasomal targeting domain, wherein the α-synuclein binding domain is derived from a reversed sequence of β-synuclein. Other methods, as well as uses and compositions, are disclosed.
7.WO/2022/167456ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTEL1 EXPRESSION
WO 11.08.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/EP2022/052417 Applicant F. HOFFMANN-LA ROCHE AG Inventor FUNDER, Erik
The present invention relates to enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity. The invention, in particular, relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention, in particular, relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
8.WO/2022/167813METHOD OF TRANSPOSON INSERTION SITE SEQUENCING CAPABLE OF UNIQUELY IDENTIFYING INSERTIONS SITES WITHIN REPEATED GENETIC ELEMENTS
WO 11.08.2022
Int.Class C12Q 1/6806
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction assay
Appl.No PCT/GB2022/050303 Applicant QUADRAM INSTITUTE BIOSCIENCE Inventor WEBBER, Mark
A method of transposon insertion sequencing (TIS) capable of resolving insertion sites in or around repeat elements, said method including the steps of; preparing a pool or library of mutant cells by introduction or insertion of one or more transposon sequences, extraction of DNA from said cells, DNA fragmentation, DNA amplification, and characterised in that the amplified DNA is sequenced by a long-read sequencing method.
9.WO/2022/168008USE OF MIRNA-485 INHIBITOR TO REGULATE PSD95, SYNAPTOPHYSIN, AND CASPASE-3 EXPRESSION
WO 11.08.2022
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No PCT/IB2022/051012 Applicant BIORCHESTRA CO., LTD. Inventor RYU, Jin-Hyeob
The present disclosure includes the use of miRNA inhibitor for treating a disease or condition associated with a decreased level of PSD95 and/or synaptophysin and/or an increased level of caspase 3 (e.g., dystonia, neuropsychiatric diseases, intellectual disability, and/or addiction). The miRNA inhibitor useful for the present disclosure can inhibit miR-485 expression and/or activity, which in turn can increase the level of PSD95 and/or synaptophysin protein of gene expression and decrease the level of caspase 3 protein or gene expression.
10.WO/2022/169913SYNTHETIC DEGRADER SYSTEM FOR TARGETED PROTEIN DEGRADATION
WO 11.08.2022
Int.Class C12N 9/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
10Transferases (2.)
Appl.No PCT/US2022/014998 Applicant OUTPACE BIO, INC. Inventor MOFFETT, Howell
A fusion protein is provided having a binding element and a degradation initiator, where the binding element selectively binds a target molecule, and the degradation initiator has a sequence isolated or derived from an E3 ligase. A composition is provided comprising: (a) a first fusion protein comprising a first binding element; and (b) a second fusion protein comprising a second binding element; wherein: (1) the first fusion protein further comprises a degradation initiator or a functional variant thereof and the second fusion protein further comprises a target molecule; or (2) the first fusion protein further comprises a target molecule and the second fusion protein further comprises a degradation initiator or a functional variant thereof. The fusion proteins and compositions may be used for the targeted degradation of endogenous and exogenous proteins, optionally, in a cell or in vivo, for the treatment or prevention of a disease or disorder.